Aptevo Therapeutics (APVO) Other Non-Current Liabilities (2015 - 2024)

Aptevo Therapeutics (APVO) posted Other Non-Current Liabilities of $14000.0 for Q3 2024, little changed sequentially from $14000.0 in Q2 2024.

Aptevo Therapeutics (APVO) Other Non-Current Liabilities (2015 - 2024) Analysis & Trends

Aptevo Therapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $14000.0 in Q3 2024.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $14000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $14000.0 (changed N/A YoY) and the FY2021 annual result came in at $15.6 million, changed N/A from the prior year.
Other Non-Current Liabilities steadied at $14000.0 in Q3 2024 per APVO's latest filing, from $14000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $23.3 million in Q1 2022 and troughed at $14000.0 in Q1 2024.
A 3-year average of $12.5 million and a median of $17.1 million in 2021 frame the typical range for Other Non-Current Liabilities.
The widest YoY moves for Other Non-Current Liabilities: up 5.28% in 2022, down 5.28% in 2022.
Over 3 years, Other Non-Current Liabilities stood at $15.6 million in 2021, then surged by 49.82% to $23.3 million in 2022, then tumbled by 99.94% to $14000.0 in 2024.
According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14000.0, $14000.0, and $14000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Aptevo Therapeutics	3.18 Mn	-6.61 Mn	-

Download Data